Tackling Problem Of 2010 Patent Expiration Influx, CareNet Expects Strong Growth
This article was originally published in PharmAsia News
The marketing research firm CareNet aims to play a critical role in tackling the so-called "problem of 2010" by providing services to bolster productivity in sales operation and information technology. In the next five years, CareNet expects to expand its membership to 130,000 from 74,000
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.